If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-ehab/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook ...

EHAB Stock Alert: Halper Sadeh LLC is Investigating Whether Enhabit, Inc. is Obtaining a Fair Price for its Shareholders-# EHAB Stock Alert: Halper Sadeh LLC is Investigating Whether Enhabit, Inc. is Obtaining a Fair Price for its ShareholdersShare---Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transaction may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and ...

Shareholder Alert: The Ademi Firm investigates whether Enhabit Inc. is obtaining a Fair Price for its Public Shareholders [Accessibility Statement] Skip NavigationMILWAUKEE, Feb. 23, 2026 /PRNewswire/ -- Ademi LLP is investigating Enhabit (NYSE: EHAB) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Kinderhook Industries.Click [here] to learn how to join our investigation and obtain additional information or contact us at [[email protected]] or t ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead ...

Core Insights - Enhabit, Inc. and Encompass Health Corporation have successfully collected $43.1 million in full satisfaction of their claims for attorneys' fees and mitigation damages [1] Legal Proceedings - The claims were filed in the Delaware Court of Chancery against former officer Chris Walker, Vistria Group senior partner David Schuppan, and Nautic Partners managing director Christopher Corey [1] - These claims are related to a December 2024 judgment that favored Enhabit and Encompass [1]

Industry Overview - The Medical Services sector is rapidly evolving due to digital health advancements, value-based care adoption, and a focus on patient-centric solutions [1] - The global healthcare analytics market is projected to grow from $56.64 billion in 2025 at a CAGR of 22.7% through 2035, benefiting payers, providers, and analytics vendors [1] - The industry includes various service providers such as pharmacy benefit managers, contract research organizations, and healthcare workforce solution providers, transitioning from volume-based to value-based care [3] Key Trends - The U.S. digital health market is expected to grow from $92.08 billion in 2025 to $248.11 billion by 2034, with a CAGR of 11.6% [4] - The global big data in healthcare market is valued at $110.97 billion in 2025, projected to grow at a CAGR of 19.2% from 2026 to 2035 [4] - Companies adopting AI technologies have seen a 50% reduction in treatment costs and over 50% improvement in patient outcomes [4] Workforce Challenges - A projected healthcare worker shortage of 100,000 by 2028, including a shortfall of 73,000 nursing assistants, is expected to elevate labor costs [2][5] - The WHO estimates a shortfall of 11 million physicians, particularly in low-income countries, emphasizing the need for workforce expansion [5] - Total hospital expenses increased by 5.1% in 2024, significantly outpacing the overall inflation rate of 2.9% [5] Company Highlights - **Medpace Holdings (MEDP)**: Expected earnings growth rate of 17.2% in 2025, with revenues projected to rise by 18.7% from 2024 [19][20] - **Enhabit, Inc. (EHAB)**: Anticipated earnings surge of 161.9% in 2025, with revenue growth of 2.3% [23][24] - **Progyny (PGNY)**: Projected earnings increase of 9.8% in 2025, with revenues expected to grow by 9.2% [26][27] Performance Metrics - The Medical Services industry has gained 6.8% over the past year, in line with the Medical sector, but lagged behind the S&P 500's 19.3% increase [10] - The industry is currently trading at a forward P/E of 16.9X, compared to the S&P 500's 23.3X and the sector's 21.6X [14]

Core Insights - The session is part of a virtual home care conference hosted by BofA Securities, featuring Enhabit, a major player in the home health and hospice sector in the U.S. [2] Company Overview - Enhabit is recognized as one of the largest home health and hospice providers in the United States [2]. Leadership - The session includes insights from Barb Jacobsmeyer, the President and CEO of Enhabit, and Ryan Solomon, the CFO [2]. Audience Engagement - The audience is encouraged to participate by submitting questions through a designated window during the Q&A session [3].

Enhabit (NYSE: EHAB) Conference Call Summary Company Overview - Enhabit is one of the largest home health and hospice providers in the U.S. [2] Key Industry Insights - The final home health rate update from CMS resulted in a better outcome than initially proposed, although it still represents a cut [2][3] - Enhabit anticipates organic profitability growth in 2026 at a similar rate to 2025, despite the negative reimbursement rate [3][5] - The final rule indicates a potential end to permanent behavior adjustments by CMS, which is viewed positively by the company [7][8] Financial Performance and Projections - The company expects to target increased investments in 2026, including de novo openings and strategic M&A, due to improved balance sheet flexibility [4][12] - Temporary adjustments from CMS are projected to recoup approximately $460 million in 2026, with a total over-reimbursement of $4.76 billion anticipated over ten years [10][11] - Approximately 20% of Enhabit's Medicare Advantage (MA) census is linked to Medicare fee-for-service [16] M&A and Investment Strategy - Enhabit plans to be disciplined in M&A, focusing on accretive transactions, particularly in home health, while hospice acquisitions may be more challenging due to high multiples [12][13] - The company is looking to increase de novo investments in hospice, particularly in overlapping markets with home health [13][57] Payer Innovation and Contract Negotiations - 57% of Enhabit's non-Medicare admissions are in payer innovation contracts, up from 52% year-over-year [19] - The company is successfully renegotiating contracts, achieving low double-digit rate increases without significant disruption [21][22] - Enhabit is focusing on moving per-visit contracts towards episodic contracts to better manage patient care [25][26] Market Dynamics and Challenges - Medicare fee-for-service admissions declined by about 3% in Q3, with Enhabit maintaining a mix of 47% Medicare and 53% MA [32][33] - The company is actively working to improve its fee-for-service mix through partnerships and community care initiatives [34][36] Cost Management and Labor - Enhabit expects a decline in cost per day due to increased volume and fixed salary costs [37] - Wage inflation is projected to remain around 3% for both home health and hospice [38][46] Growth Projections - Long-term growth for both home health and hospice is expected to be in the mid to high single digits [43][49] - The hospice segment has seen robust growth, with 25% of hospice admissions coming from home health [59] Corporate Financial Health - Enhabit exited the quarter with a leverage ratio of 3.9, with plans to maintain flexibility while pursuing targeted acquisitions [60][61] - The company aims to balance free cash flow deployment with deleveraging efforts [62] Conclusion - Enhabit is positioned for growth through strategic investments, disciplined M&A, and a focus on improving profitability despite regulatory challenges in the home health and hospice sectors [4][12][60]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lead to investments with limited upside or potential downside [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify promising candidates [3] Group 2: Case Study - Enhabit (EHAB) - Enhabit (EHAB) has shown a price increase of 1.6% over the past four weeks, indicating growing investor interest [4] - The stock has gained 10.7% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [5] - EHAB has a beta of 1.69, suggesting it moves 69% more than the market in either direction, indicating fast-paced momentum [5] Group 3: Valuation and Earnings Estimates - EHAB has a Momentum Score of B, suggesting it is an opportune time to invest in the stock [6] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which typically attract more investor interest [7] - EHAB is trading at a Price-to-Sales ratio of 0.42, indicating it is relatively undervalued, as investors pay only 42 cents for each dollar of sales [7] Group 4: Additional Opportunities - Besides EHAB, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies to help identify potential winning stock picks based on various investing styles [9]

Core Insights - The company has seen success in its strategies implemented over the past few years, particularly in hospice care, which continues to outperform expectations [1] - The payer strategy in home health is beginning to yield positive results, especially in negotiations with various payers [1] - The company has focused on reducing leverage, which has contributed to improved free cash flow [1] - Overall performance for 2025 is viewed positively, with a strong start to the fourth quarter [1]